Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at Upcoming 2021 American Academy of Neurology Virtual Annual Meeting, Highlighting Teva’s Ongoing Commitment to Neurology

Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 19 presentations examining clinical and real-world data for AJOVY^® (fremanezumab-vfrm) injection and AUSTEDO^® (deutetrabenazine) tablets will be presented at the upcoming 2021 American Academy of Neurology (AAN) Virtual Annual Meeting, taking place April 17-22.

“We are committed to improving the lives of patients and further evaluating AJOVY and AUSTEDO so we can continue to help healthcare professionals and patients make informed treatment decisions,” said Denisa Hurtukova, MD, VP, Head of North America Medical Affairs. “The data being presented at this year’s AAN meeting offer important information on the integrated safety of AUSTEDO as well as clinical analyses and real-world experience of patients treated with AJOVY.”

At this year’s AAN, Teva’s neurology portfolio will highlight integrated safety data for AUSTEDO in the treatment of both tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). The analysis examined safety by comparing the incidence of adverse events with AUSTEDO versus placebo in: two pivotal TD studies (ARM-TD and AIM-TD) and through week 15 of an open-label extension study (RIM-TD); as well as data in HD patients captured upon first exposure to AUSTEDO in the First-HD pivotal trial and through week 15 of a long-term open label extension trial (ARC-HD).

Other AUSTEDO posters include an analysis of real-world adherence patterns with AUSTEDO and tetrabenazine among patients diagnosed with HD, as well as the impact on quality of life of different severity levels of chorea associated with HD.

AJOVY data being presented include results from clinical and real-world analyses. The data being presented at the meeting spans 17 posters and include post-hoc Phase 3 data examining the long-term response of AJOVY in patients who initially did not respond to treatment, an analysis of real-world treatment patterns for patients prescribed AJOVY, and a retrospective evaluation of quarterly and monthly dosing with AJOVY in a real-world setting.

This year’s annual AAN meeting is fully virtual. Data presentations can be accessed by registering for the meeting.

The full set of Teva-sponsored neurology portfolio data to be presented includes:

AJOVY^®:

De novo

• P10.023 Long-term Efficacy of Fremanezumab in Patients with Chronic or Episodic Migraine Who Were Inadequate Responders to Initial Fremanezumab Treatment
• P10.031 US Real-world Effectiveness of Quarterly and Monthly Fremanezumab for Reducing Migraine Days and Headache Days in Adult Patients with Migraine
• P10.088 US Real-World Patient Characteristics, Acute Medication Use, and Treatment Patterns for Patients Initiating Fremanezumab
• P10.021 Early Reductions in Headache Severity and Duration With Fremanezumab Treatment in the Randomized, Double-blind Phase 3b FOCUS study
• P10.125 Effect of Fremanezumab on the Total Burden of Migraine in Patients with Episodic or Chronic Migraine: Findings from 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
• P10.120 Real-world Reductions in Migraine and Headache Days for Patients With Chronic and Episodic Migraine Initiating Fremanezumab in the US
• P10.051 US Real-world Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab
• P10.122 Baseline Comorbidities and Changes in Acute Medication Use by Quarterly and Monthly Dosing Regimen in Patients Prescribed AJOVY in US Physician Practices
• P10.046 Efficacy of Fremanezumab in Patients With Moderate and Higher Frequency Episodic Migraine
• P10.024 Efficacy of Fremanezumab in Patients With Lower and Higher Frequency Chronic Migraine
• P10.029 A Phase 2 Study of Fremanezumab as a Treatment for Posttraumatic Headache in Adult Patients

Encore:

• P10.121 Improvements in Patient-reported Migraine Pain Intensity and Composite Migraine Symptoms With Fremanezumab in the Real World
• P10.119 Real-world Adherence, Persistence, Switching, and Reinitiation in Patients Prescribed AJOVY in US Physician Practices
• P10.123 Real-World Adherence, Persistence, Switching, and Reinitiation by Quarterly and Monthly Dosing Regimen in Patients Prescribed AJOVY in US Physician Practices
• P10.118 Number Needed to Treat/Harm for Fremanezumab in Patients Who Had Inadequate Response to 2-4 Prior Migraine Preventive Medication Classes
• P10.034 Cardiovascular Safety of Fremanezumab in Patients With Migraine and Cardiovascular Medical History or Risk Factors: a Pooled Analysis of Phase 3 Studies
• P10.007 Efficacy in Patients Switching from Quarterly to Monthly Fremanezumab or Maintained on Monthly Fremanezumab Treatment Over 6 Months in the Phase 3b FOCUS Study

AUSTEDO^®:

De novo:

• P14.136 Incidence of Adverse Events Associated With Deutetrabenazine for the Treatment of Tardive Dyskinesia and Cho